Meta‐analysis of completion lymph node dissection in sentinel lymph node‐positive melanoma. BJS 2019; 106: 672-681.
Published: 26th March 2019
Authors: C. V. Angeles, R. Kang, K. Shirai, S. L. Wong
The role of completion lymph node dissection (CLND) in patients with sentinel lymph node (SLN)‐positive melanoma continues to be debated. This systematic review and meta‐analysis evaluated survival and recurrence rate in these patients who underwent CLND, compared with observation.
A comprehensive MEDLINE and Embase database search was performed for cohort studies and RCTs published between January 2000 and June 2017 that assessed the outcomes of CLND compared with observation in patients with SLN‐positive melanoma. The primary outcome was survival and the secondary outcome was recurrence rate. Studies were assessed for quality using the Cochrane risk‐of‐bias tool for RCTs and Newcastle–Ottawa Scale for cohort studies. Pooled relative risk or hazard ratio with 95 per cent confidence intervals were calculated for each outcome. The extent of heterogeneity between studies was assessed with the I2 test. The protocol was registered in PROSPERO (CRD42017070152).
Fifteen studies (13 cohort studies with 7868 patients and 2 RCTs with 2228 patients) were identified for qualitative synthesis. Thirteen studies remained for quantitative meta‐analysis. Survival was similar in patients who underwent CLND and those who were observed (risk ratio (RR) for death 0·85, 95 per cent c.i. 0·71 to 1·02). The recurrence rate was also similar (RR 0·91, 0·79 to 1·05).
Patients with SLN‐positive melanoma do not have a significant benefit in survival or recurrence rate if they undergo CLND rather than observation.Full text
You may also be interested in
Randomized clinical trial
Randomized clinical trial of open suture repair versus totally extraperitoneal repair for treatment of sportsman’s hernia. BJS 2019; 106: 837-844.
Authors: A. J. Sheen, A. Montgomery, T. Simon, I. Ilves, H. Paajanen
Randomized clinical trial
Randomized clinical trial comparing total extraperitoneal with Lichtenstein inguinal hernia repair (TEPLICH trial). BJS 2019; 106: 845-855.
Authors: N. Gutlic, A. Gutlic, U. Petersson, P. Rogmark, A. Montgomery
Authors: I. R. Daniels, N. J. Smart
Authors: A. S. H. M. van Dalen, J. Legemaate, W. S. Schlack, D. A. Legemate, M. P. Schijven
Authors: R. L. Harries, J. Glasbey, V. J. Gokani, G. Griffiths, W. Allum
Authors: K. Fairhurst, J. M. Blazeby, S. Potter, C. Gamble, C. Rowlands, K. N. L. Avery et al.
Incidence and lifetime risk of hospitalization and surgery for diverticular disease. BJS 2019; 106: 930-939.
Authors: F. Sköldberg, J. Granlund, A. Discacciati, F. Hjern, P. T. Schmidt, O. Olén et al.
Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system. BJS 2019; 106: 889-897.
Authors: N. Chereau, T. O. Oyekunle, A. Zambeli‐Ljepović, H. S. Kazaure, S. A. Roman, F. Menegaux et al.
Long‐term results from a randomized comparison of open transinguinal preperitoneal hernia repair and the Lichtenstein method (TULIP trial). BJS 2019; 106: 856-861.
Authors: W. J. V. Bökkerink, G. G. Koning, D. Malagic, L. Hout, C. J. H. M. Laarhoven, P. W. H. E. Vriens et al.
Authors: G. Ramsay, A. B. Haynes, S. R. Lipsitz, I. Solsky, J. Leitch, A. A. Gawande et al.